10-Q: Bionano Genomics Reports Second Quarter 2024 Results, Focuses on Cost Savings and Strategic Review

Bionano Genomics' Q2 2024 results show a decrease in revenue and a net loss, alongside significant cost-cutting measures and a strategic review of options.

Summary

• Bionano Genomics reported a net loss of $16.2 million for the three months ended June 30, 2024, and $47.6 million for the six months ended June 30, 2024.
• Total revenue decreased by 10% to $7.77 million for the three months ended June 30, 2024, compared to $8.66 million for the same period in 2023.
• Product revenue decreased slightly by 1% to $6.51 million, while service and other revenue decreased by 39% to $1.26 million for the three months ended June 30, 2024.
• The company's installed base of OGM systems grew by 29% year-over-year to 363 as of June 30, 2024.
• Bionano sold 6,165 flowcells in the three-month period ended June 30, 2024, a decrease of approximately 13% from 7,062 flowcells sold in the same quarter of 2023.
• The company implemented a cost savings plan in March 2024, aiming to reduce annualized operating expenses by $35 to $40 million starting in the second half of 2024, including a reduction of approximately 120 employees.
• Bionano has an accumulated deficit of $628.9 million as of June 30, 2024, and used $49.1 million in cash in operations during the six months ended June 30, 2024.
• The company issued $20 million of Senior Secured Convertible Debentures in May 2024 for $18 million in gross proceeds.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the six months ended June 30, 2024, are issued.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments, such as the growth in the installed base and the cost savings plan, but the significant net losses, declining revenue, and going concern warning overshadow these positives. The company is facing significant financial challenges and uncertainty about its future.

Positives

• The installed base of OGM systems continues to grow, indicating increasing adoption of the technology.
• Flowcell sales increased by 12% in the first six months of 2024 compared to the same period in 2023.
• The cost savings plan is expected to significantly reduce operating expenses.
• The company has fully redeemed the High Trail Notes, removing a significant debt obligation.
• The company has secured additional funding through the issuance of convertible debentures and common stock.

Negatives

• The company experienced a net loss of $16.2 million for the three months ended June 30, 2024, and $47.6 million for the six months ended June 30, 2024.
• Total revenue decreased by 10% for the three months ended June 30, 2024, compared to the same period in 2023.
• Flowcell sales decreased by 13% in the three-month period ended June 30, 2024, compared to the same period in 2023.
• Service and other revenue decreased by 39% for the three months ended June 30, 2024, due to the phasing out of certain testing services.
• The company has an accumulated deficit of $628.9 million as of June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.

Risks

• The company has experienced recurring net losses and negative cash flows, raising concerns about its ability to continue as a going concern.
• The company's future capital needs are uncertain, and it may require additional funding to continue operations.
• The terms of the Debentures and the Debenture Purchase Agreement restrict the company's current and future operations.
• Unfavorable geopolitical and macroeconomic developments could adversely affect the company's business and financial results.
• The company's products and technologies may not achieve sufficient market acceptance.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, and rules related to data privacy and security.
• If the FDA ends enforcement discretion for Laboratory Developed Tests or determines that the company's RUO products are medical devices, the company may be required to obtain regulatory clearances or approvals.
• The company depends on technology that is licensed to it by third parties, and any loss of these rights could prevent the company from selling its products.
• The price of the company's securities has been and may in the future be volatile or may decline regardless of the company's operating performance.

Future Outlook

Management expects operating losses and negative cash flows to continue for at least the next year. The company is actively evaluating debt and equity financing sources as well as cost reduction strategies. Based on current business plans, the company believes that existing cash and cash equivalents and short-term investments will be sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2024.

Management Comments

• Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to product development and commercialization efforts.
• Management has prepared cash flows forecasts which indicate that based on the Companys expected operating losses and negative cash flows, there is substantial doubt about the Companys ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the six months ended June 30, 2024, are issued.
• Managements ability to continue as a going concern is dependent upon its ability to raise additional funding.
• The board of directors (the Board) has established a strategy committee to work with the Company and outside advisors in evaluating our options and considering alternatives that we believe will maximize stakeholder value, including any of the following or a combination thereof: debt financing, equity investments, combinations with other companies, or the sale of all or part of the company.

Industry Context

The company operates in the competitive life sciences research and diagnostic markets, facing competition from both established and early-stage companies. The company's performance is influenced by levels of research and development spending by clinical research laboratories, academic and governmental research institutions, and biopharmaceutical companies.

Comparison to Industry Standards

• Bionano's revenue growth is below that of some competitors in the genomics space, such as PacBio and Oxford Nanopore, which have seen more rapid adoption of their sequencing technologies.
• The company's reliance on a single contract manufacturer for its OGM systems and chip consumables is a risk, as many companies in the industry diversify their supply chains.
• The company's cash burn rate is high compared to industry benchmarks, and its ability to raise additional capital is uncertain.
• The company's decision to phase out certain testing services related to neurodevelopmental disorders is a strategic shift that may impact its revenue stream, while other companies in the diagnostic space are expanding their service offerings.
• The company's restructuring efforts and cost-cutting measures are similar to actions taken by other companies in the industry facing financial challenges, but the success of these measures remains to be seen.

Stakeholder Impact

• Shareholders may experience dilution if the company issues equity securities to raise additional funds.
• Employees have been affected by the reduction in force, with approximately 120 employees being laid off.
• Customers may be affected by the phasing out of certain testing services.
• Creditors may be affected by the company's financial challenges and potential inability to continue as a going concern.

Next Steps

• The company will continue to seek additional capital to fund its operations.
• The company will continue to implement its cost savings plan.
• The company will continue to evaluate strategic alternatives to maximize stakeholder value.
• The company will continue to monitor and comply with various applicable guidelines and legal requirements in the jurisdictions in which it operates.

Key Dates

Keywords

Optical Genome Mapping, OGM, Genomics, BioDiscovery, Purigen, Next-Generation Sequencing, VIA Software, Flowcells, Convertible Debentures, Cost Savings, Financial Results, Restructuring, Capital Raise, Debt Financing, Liquidity, Going Concern